Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328297 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-55308942 in the Treatment of Bipolar Depression
A Phase 2 study, sponsored by Janssen Pharmaceutica N.V., Belgium.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT05328297 is a Phase 2 study that has completed, run by Janssen Pharmaceutica N.V., Belgium. The registered enrollment target is 116 participants.
The verdict
NCT05328297, a Phase 2 study, has completed, sponsored by Janssen Pharmaceutica N.V., Belgium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
Interventions
- DRUG Placebo
- DRUG JNJ-55308942
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05328297
The ClinicalTrials.gov registry entry for NCT05328297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Pharmaceutica N.V., Belgium, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05328297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05328297 about?
NCT05328297 is a clinical study titled "A Study of JNJ-55308942 in the Treatment of Bipolar Depression". The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
What is the current status of trial NCT05328297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2022-06-03. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT05328297?
The interventions under investigation include: Placebo (DRUG), JNJ-55308942 (DRUG).
Who is sponsoring clinical trial NCT05328297?
This trial is sponsored by Janssen Pharmaceutica N.V., Belgium, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.